Lilly pens $1.2B deal for Hanmi’s GLP-2 drug being aimed at short bowel syndrome

Eli Lilly has expanded its glucagon-like peptide (GLP) portfolio in an intriguing direction by licensing a phase 2-stage GLP-2 agonist from Hanmi Pharm. Eli Lilly has expanded its glucagon-like peptide portfolio in an intriguing direction by licensing a phase 2-stage GLP-2 agonist from Hanmi Pharm. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry Events Webinars…

Source: FierceBiotech